Reward Processing and Depressive Subtypes: Identifying Neural Biotypes

Conditions

• Anhedonia
• Depression
• Depressive Disorder
• Depressive Symptoms
• Major Depressive Disorder
• Major Depressive Episode

Eligibility Criteria

Sex

ALL

Age

18 Years - 70 Years

Healthy Volunteers

Accepted

Interventions

• cross-sectional MRI and EEG assessments (NO INTERVENTION) — OTHER
  n/a there is no intervention in this observational study

Study Details

Deficits in motivation and pleasure are common in depression, and thought to be caused by alterations in the ways in which the brain anticipates, evaluates, and adaptively uses reward-related information. However, reward processing is a complex, multi-circuit phenomenon, and the precise neural mechanisms that contribute to the absence or reduction of pleasure and motivation are not well understood. Variation in the clinical presentation of depression has long been a rule rather than an exception, including individual variation in symptoms, severity, and treatment response. This heterogeneity complicates understanding of depression and thwarts progress toward disease classification and treatment planning. Discovery of depression-specific biomarkers that account for neurobiological variation that presumably underlies distinct clinical manifestations is critical to this larger effort.

Key Dates

Start date

Jun 1, 2021

Status verified

Jul 2024

Primary completion

Jun 1, 2025

Completion

Sep 1, 2025

Study Design

Enrollment

150 participants (estimated)

Arms

• Arm: MDD (Major Depressive Disorder) Group
  Individuals (ages 18-70 years) who meet DSM-5 criteria for MDD, as assessed using the Structured Clinical Interview for DSM-5 (SCID-5), with Stable psychiatric medication regime for \> 1 month will be recruited for participation in EEG and fMRI sessions in this observational study.
• Arm: Unaffected Comparison Group
  50 unaffected comparison participants will be matched as a group to the age, race, educational level, handedness, and parental socio-economic status of the MDD patient group will be recruited for participation in EEG and fMRI testing sessions identical to those administered to the patients

Primary Outcome Measure

Stimulus preceding negativity [ Time Frame: 1 month (EEG measure of reward anticipation) ]

Central Contacts

• Jason Hemmerle, MBA
  415 221 4810
  [email protected]
• Kaitlyn Dal Bon, BA
  415 221 4810
  [email protected]

Locations (1)

Find similar trials in San Francisco, CA

Related Studies

• A Phase I/II Study of PDC-1421 for Treating Depression in Cancer Patients
  PHASE1/PHASE2 · Not Yet Recruiting · BioLite, Inc. · Los Angeles, California
• Closed-Loop Deep Brain Stimulation for Major Depression
  Recruiting · Andrew Krystal · San Francisco, California
• Spectral TMS (s-TMS)
  Enrolling By Invitation · University of California, Los Angeles · Los Angeles, California
• Biomarker-guided rTMS for Treatment Resistant Depression
  PHASE3 · Recruiting · Weill Medical College of Cornell University · Stanford, California